Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs Tempus AI — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B), while Tempus AI trades at $69.85 (market cap $12.77B). The key difference: Tempus AI is far larger — about 7.5× Nuvation Bio Inc. Class A Common Stock's market cap, and Tempus AI is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Tempus AI for 22 Days on average.
| NUVB | TEM | |
|---|---|---|
Market Cap | $1.71B | $12.77B |
Volume | 5,448,712 | 8,980,490 |
Sector | Health | Broad Market / Factor |
52-Week High | $9.54 | $99.28 |
52-Week Low | $3.41 | $41.55 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $1.30B | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
